Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in refractory IgA nephropathy and IgA vasculitis nephritis in children (real-world, single-arm)
ChiCTR2500111370Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Oct 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in IgA nephropathy (IgAN) and IgA vasculitis nephritis, sponsored by First Hospital of China Medical University. Primary endpoint: 24-hour urine protein level changes. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)IgA vasculitis nephritis
Beyond the preview
Go deeper on ChiCTR2500111370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111370.